Jefferies Analyst Issues Buy Rating for Werewolf Therapeutics with $4 Price Target

martes, 5 de agosto de 2025, 5:52 am ET1 min de lectura
HOWL--

Werewolf Therapeutics has received a Buy rating and $4.00 price target from Jefferies analyst Farzin Haque. The company's shares closed at $1.16 on Friday. TipRanks reports that Haque has a success rate of 20.00% and an average return of -38.8%. There is a Strong Buy analyst consensus rating for Werewolf Therapeutics with an average price target of $8.20.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios